280
Kronik HDV
in interferonalpha- stimulated host cells. J Viral Hepat 2006; 13: 150-157
13.
Babiker ZO, Hogan C, Ustianowski A, Wilkins E. Does interferon-sparing tenofovir
disoproxil fumarate-based therapy have a role in the management of severe acute
hepatitis delta superinfection? J Med Microbiol 2012; 61: 1780-1783
14.
Nisini R, Paroli M, Accapezzato D, et al. Human CD4+ T-cell response to hepatitis
delta virus: identification of multiple epitopes and characterization of T-helper
cytokine profiles. J Virol 1997; 71: 2241–51.
15.
Kuhla A, Eipel C, Abshagen K, Siebert N, Menger MD, Vollmar B. Role of the
perforin/granzyme cell death pathway in D-Gal/LPS-induced inflammatory liver
injury. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1069-G1076
16.
Aslan N, Yurdaydin C, Wiegand J, et al. Cytotoxic CD4 T cells in viral hepatitis. J
Viral Hepatol 2006; 13: 505–14.
17.
S, Craxì A, Carini C, Colombo P, di Blasi F, Spinelli G, Fratazzi C, Messina MC,
Antonelli G, Ausiello C. Interleukin-2, interleukin-2 receptor and gamma-interferon
synthesis by peripheral blood mononuclear cells in chronic hepatitis delta virus
infection. J Hepatol 1989; 8: 358-366
18.
Franco A, Barnaba V, Natali P, Balsano C, Musca A, BalsanoF. Expression of class
I and class II major histocompatibility complex antigens on human hepatocytes.
Hepatology 1988; 8:449-454
19.
Wedemeyer H, Ciner A, Yurdaydin C, et al. Diff erential cytokine pattern of HDV-
specifi c cellular immune responses distinguishes treatment responder and
nonresponder to PEG-IFN?-2a treatment: results from the HEP-NET/International
HIDIT-1 study. J Hepatol 2007; 46 (suppl 1): S13–14.
20.
Greco-Stewart V, Pelchat M. Interaction of host cellular proteins with components
of the hepatitis delta virus. Viruses 2010; 2: 189-212
21.
Philipp T, Durazzo M, Trautwein C, et al. Recognition of uridine diphosphate
glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet
1994;344:578-81.
22.
Fiedler M, Roggendorf M. Immunology of HDV infection. Curr Top Microbiol
Immunol 2006; 307: 187-209
23.
Hansson BG, Riesbeck K, Nordenfelt E, Weiland O. Successful treatment of
fulminant hepatitis B and fulminant hepatitis B and D coinfection explained by
inhibitory effect on the immune response? Prog Clin Biol Res 1991; 364: 421-427
24.
Hourioux C, Sureau C, Poisson F, Brand D, Goudeau A, Roingeard P. Interaction
between hepatitis delta virus-encoded proteins and hepatitis B virus envelope
protein domains. J Gen Virol 1998; 79 ( Pt 5): 1115-1119
25.
Williams V, Brichler S, Radjef N, et al. Hepatitis delta virus proteins repress hepatitis
B virus enhancers and activate the alpha/beta interferon-inducible MxA gene. J
Gen Virol 2009; 90: 2759–67.
26.
Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, Ronchi G,
Colombo M. A 28-year study of the course of hepatitis Delta infection: a risk factor
for cirrhosis and hepatocellular carcinoma. Gastroenterology 2009; 136: 1629-1638
27.
Wu JC, Chen TZ, Huang YS, et al. Natural history of hepatitis D viral superinfection:
significance of viremia detected by polymerase chain reaction. Gastroenterology
1995;108:796–802.
28.
Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of
hepatitis D: Update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010;
7:31-40.
29.
Su CW, Huang YH, Huo TI, et al. Genotypes and viremia of hepatitis B and
